Communiqués Vaccinex, Inc.

Actions

VCNX

US9186403013

Recherche biotechnologique et médicale

Temps Différé OTC Markets 15:36:34 06/10/2026			Varia. 5j.	Varia. 1 janv.
1,060 ^USD	+5,16%		+3,41%	-1,44%

08/07	Vaccinex, Inc. présente de nouvelles données sur les biomarqueurs et annonce un essai clinique de phase 2B pour le pepinemab dans la maladie d'Alzheimer	CI
23/12	Vaccinex, Inc. conclut un accord de partage de revenus de 60 millions de dollars avec Pepinemab Development Venture, LP	CI

Communiqués

08/07	Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026	AQ
30/04	Vaccinex Reports 2025 Annual Financial Results	AQ
23/12	Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease	AQ
03/12	Vaccinex : CTAD 2025 Oral Communication	PU
27/05/25	Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting	AQ
21/04/25	Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)	AQ
08/04/25	Vaccinex : 19th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD25) Presentation	PU
08/04/25	Vaccinex : Advanced Therapies Xchange Presentation	PU
07/04/25	Vaccinex : AACR8172 DC Poster	PU
07/03/25	Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market	AQ
17/12/24	Vaccinex : Announces Receipt of Delisting Notification from Nasdaq Form 8 K	PU
17/12/24	Vaccinex Announces Receipt of Delisting Notification from Nasdaq	AQ
18/11/24	Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update	AQ
09/11/24	Vaccinex : ActivMab SITC Poster	PU
08/11/24	Vaccinex : Oncology SITC Poster	PU
07/11/24	Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC	AQ
05/11/24	Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting	AQ
31/10/24	Vaccinex : CTAD 2024 Pepinemab for VCNX Presentation	PU
31/10/24	Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain	AQ
24/10/24	Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024	AQ
18/09/24	Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds	AQ
15/08/24	Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's disease and Plans to Pursue a Development Partnership	AQ
14/08/24	Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership	AQ
01/08/24	Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's disease	AQ
31/07/24	Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease	AQ